BELKYRA / KYBELLA Double Chin Treatment: from $1500
Health Canada approved non-invasive injectable permanently eliminates unwanted fat under the chin (commonly referred to as a double chin) and contour your chin profile.
HOW DOES IT WORK?
BELKYRA breaks down unwanted localized fat under the chin area which helps reduce and eventually eliminates a double chin. It contains the active ingredient deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath your chin, it causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
WHAT CAN I EXPECT DURING MY APPOINTMENT?
Your BELKYRA injection will be performed by Dr. Barnard, MD in our conveniently located medical spa in the heart of Windsor, Ontario. Our trained clinicians will begin by prepping you for your treatment which involves cleaning the area to be treated and placing a injection grid on your neck. The doctor will inject small amounts of this injectable directly into the unwanted fat. A typical treatment takes approximately 45 minutes.
It is normal to experience minor swelling in the treatment area. Some patients also report minor bruising, pain, numbness, redness, and areas of hardness in the treatment area.
WHEN WILL I SEE RESULTS & HOW LONG DO RESULTS LAST?
Results will vary per individual based on the amount of subcutaneous fat in the double chin. Most patients will need between 2 to 6 injections to reach their desired results. Treatments must be spaced at least one month apart. Patients report seeing their Belkyra results four to six weeks after each treatment.
Once the desired aesthetic response is achieved re-treatment is not expected. You can return to your regular daily routine immediately after your Belkyra injection, no downtime is needed.
PRECAUTIONS
You should not receive this double chin treatment if you have an infection in the treatment area, are pregnant, plan to become pregnant, breastfeeding or plan to breastfeed, have difficulty swallowing, nerve injuries or weakness in the lower face. Discuss with your doctor if you are taking prescription and other medication that could be blood thinners (anticoagulants).
PRE & POST TREATMENT GUIDES
- Ensure you have 4 full days to recover before returning to work or important social engagements.
- 10 days before treatment: Avoid aspirin.
- 5 days before treatment: Avoid ibuprofen (Motrin, Advil), other non-steroidal medications (Aleve) and Vitamin E, St. John’s Wort, & fish oil supplements. Consult doctor prior to discontinuing prescribed medications.
- 1 hr before treatment: To avoid possible discomfort, you may take 1g of acetaminophen (i.e. Tylenol) or NSAIDs (such as ibuprofen).
- Ibuprofen (Motrin, Advil) & Zyrtec (antihistamine) may be taken for discomfort & itching.
- Treated areas should not be scratched, picked or trauma-tized in any way. Do not massage or manipulate injection site.
- Swelling & redness is expected after treatment. You may also experience bruising, pain, numbness, & induration this can last up to 14 days.
- For 72 hrs following treatment: Sleep with your head elevat-ed (2 to 3 pillows) to reduce swelling.
- For 3 days following treatment: A cool compress can be applied to the area for a maximum of 20 minutes per hour (this is not required).
- For 3 days following treatment: Avoid strenuous activities.
- Cleanse gently with non-irrating cleansers.
- A loose scarf or other neck covering can be used to camou-flage any swelling or bruising during recovery.
- If you have any difficulty swallowing, crusting or scabbing, asymmetry of your smile, contact the spa.
BELKYRA® / KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information
INDICATION
BELKYRA® / KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of BELKYRA® / KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
BELKYRA® / KYBELLA® is contraindicated in the presence of infection at the injection sites.
WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). BELKYRA® / KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of BELKYRA® / KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with BELKYRA® / KYBELLA® experienced hematoma/bruising. BELKYRA® / KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, BELKYRA® / KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of BELKYRA® / KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.
Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of BELKYRA® / KYBELLA®. Do not administer BELKYRA® / KYBELLA® into affected area until complete resolution.
ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see BELKYRA® / KYBELLA® full Prescribing Information.